Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer NCI Case Control Study

摘要

Objectives: To assess the efficacy of cytoreductive surgery (CRS) combined with hyperthermic intraperitonealchemotherapy (HIPEC) in recurrent platinum-sensitive ovarian cancer patients in comparison with standard intravenouschemotherapy in terms of progression free survival and overall survival. Methods: Retrospective case control studymatching 15 cases with 20 controls with at least 24 months of follow up. Results: The two groups were comparableand well matched in all aspects. Median follow up was 36 months in cases and 38 months in controls. The PFS2revealed a median of 6 months (range 2-14) in cases and 5 months (range 2-18) in controls. The median OS was 36and 38 months in cases and controls respectively. No statistically significant difference between the cases and controlswere observed in progression free survival (PFS2) and overall survival OS (P-value, 0.350 and 0.711 respectively).However, the PFS2 was in favor of cases and OS was in favor of controls without reaching significance. The percentageof patients who survived 5 years or more was 20% in cases and 35% in controls. The only issue in favor of HIPECis the significant reduction in chemotherapeutic toxicity when given by the intraperitoneal way (P- value 0.003).Conclusion: According to our study, CRS and HIPEC do not seem to have impact on OS and PFS in the setting ofrecurrent platinum sensitive ovarian cancer. However, we recommend on going researches with much more refinedselection criteria and with larger sample size.